ExodusPoint Capital Management LP Purchases Shares of 22,153 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

ExodusPoint Capital Management LP acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 22,153 shares of the company's stock, valued at approximately $916,000.

Other hedge funds also recently bought and sold shares of the company. Jones Financial Companies Lllp grew its stake in shares of Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after buying an additional 357 shares during the last quarter. Legato Capital Management LLC boosted its position in Mirum Pharmaceuticals by 7.9% during the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company's stock valued at $554,000 after acquiring an additional 977 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Mirum Pharmaceuticals by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company's stock worth $421,000 after purchasing an additional 1,003 shares in the last quarter. Rhumbline Advisers lifted its position in Mirum Pharmaceuticals by 2.4% during the 4th quarter. Rhumbline Advisers now owns 53,113 shares of the company's stock valued at $2,196,000 after acquiring an additional 1,236 shares during the period. Finally, Swiss National Bank grew its holdings in Mirum Pharmaceuticals by 1.9% in the fourth quarter. Swiss National Bank now owns 70,300 shares of the company's stock worth $2,907,000 after purchasing an additional 1,300 shares during the period.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM traded down $0.61 during trading hours on Wednesday, hitting $38.02. The company's stock had a trading volume of 36,008 shares, compared to its average volume of 520,231. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company has a market cap of $1.86 billion, a P/E ratio of -18.82 and a beta of 1.00. The company's 50 day simple moving average is $45.92 and its two-hundred day simple moving average is $44.01. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $99.41 million during the quarter, compared to analysts' expectations of $96.64 million. As a group, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MIRM has been the topic of a number of analyst reports. Robert W. Baird boosted their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday, February 27th. HC Wainwright increased their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of "Buy" and an average price target of $58.20.

Insider Activity

In other news, COO Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $152,241.84. Following the transaction, the chief operating officer now owns 29,588 shares in the company, valued at $1,417,856.96. This trade represents a 9.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Joanne Quan sold 6,969 shares of Mirum Pharmaceuticals stock in a transaction on Friday, January 17th. The shares were sold at an average price of $45.86, for a total value of $319,598.34. Following the transaction, the insider now owns 5,649 shares in the company, valued at $259,063.14. This trade represents a 55.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 123,442 shares of company stock valued at $5,568,733 in the last quarter. 22.87% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.